MicroRNA‑150 inhibitors enhance cell apoptosis of melanoma by targeting PDCD4

Wan,Jianji; Yang,Jie; Huang,Yueshen; Deng,Liehua

doi:10.3892/ol.2017.7445

MicroRNA‑150 inhibitors enhance cell apoptosis of melanoma by targeting PDCD4

Authors:
- Jianji Wan
- Jie Yang
- Yueshen Huang
- Liehua Deng
View Affiliations

Affiliations: Department of Dermatology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510632, P.R. China, Department of Dermatology, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, Guangdong 510080, P.R. China
Published online on: November 20, 2017 https://doi.org/10.3892/ol.2017.7445
Pages: 1475-1482
Copyright: © Wan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma is a tumor with a high mortality rate. Previous studies have demonstrated that the oncogenesis of melanoma is associated with microRNA (miR)‑150. However, the role of miR‑150 in melanoma and its regulatory mechanisms are still unclear. In the present study, melanoma cancer tissues and adjacent normal tissues were obtained from 20 melanoma patients. The expression level of miR‑150 in melanoma tissue and cell lines was detected by reverse transcription‑quantitative polymerase chain reaction. miR‑150 inhibitors/negative control were transfected into melanoma A375 cells in order to investigate the effects of miR‑150 on cell proliferation, apoptosis, cell cycle migration and invasion using a Cell Counting Kit‑8, colony formation, Hoechst 33528, flow cytometry, and Transwell assays. The association between miR‑150 and programmed cell death protein‑4 (PDCD4) was detected by a dual luciferase reporter assay. The functional role of PDCD4 in miR‑150‑affected melanoma cells was confirmed by small interfering (si)RNA knockdown. Results demonstrated that miR‑150 was significantly upregulated and mRNA and protein expressions of PDCD4 were decreased in melanoma cancer tissues as compared with adjacent normal tissues. The level of PDCD4 was inversely associated with the level of miR‑150. Transfection of miR‑150 inhibitors suppressed cell proliferation, migration, and invasion, while the apoptosis of cells was promoted and G2/M cell arrest was induced. MiR‑150 inhibitors enhanced the expression of caspase‑8 and p21. The PDCD4 was identified as a direct target gene of miR‑150. The effects of miR‑150 inhibitors on apoptosis and apoptosis‑associated proteins, including caspase‑8 and p21, of A375 cells, were reversed following transfection of siRNA‑PDCD4. Therefore, miR‑150 inhibitors enhance cell apoptosis via upregulation of PDCD4‑mediated activation of caspase‑8 and p21. These findings demonstrate the potential for a promising therapeutic strategy in the management of melanoma.

View Figures

View References

1	Kosary CL, Altekruse SF, Ruhl J, Lee R and Dickie L: Clinical and prognostic factors for melanoma of the skin using SEER registries: Collaborative stage data collection system, version 1 and version 2. Cancer. 23 Suppl 120:S3807–S3814. 2014. View Article : Google Scholar
2	Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE III, Daniels GA, Daud A, Dimaio D, Fleming MD, et al: Melanoma, version 4.2014. J Natl Compr Canc Netw. 12:621–629. 2014. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
5	Rastrelli M, Tropea S, Rossi CR and Alaibac M: Melanoma: Epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 28:1005–1011. 2014.PubMed/NCBI
6	Hao M, Zhao G, Du X, Yang Y and Yang J: Clinical characteristics and prognostic indicators for metastatic melanoma: Data from 446 patients in north China. Tumour Biol. 37:10339–10348. 2016. View Article : Google Scholar : PubMed/NCBI
7	Song X, Zhao Z, Barber B, Farr AM, Ivanov B and Novich M: Overall survival in patients with metastatic melanoma. Curr Med Res Opin. 31:987–991. 2015. View Article : Google Scholar : PubMed/NCBI
8	Eriksson H, Frohm-Nilsson M, Järås J, Kanter-Lewensohn L, Kjellman P, Månsson-Brahme E, Vassilaki I and Hansson J: Prognostic factors in localized invasive primary cutaneous malignant melanoma: Results of a large population-based study. Br J Dermatol. 172:175–186. 2015. View Article : Google Scholar : PubMed/NCBI
9	Pan Y, Haydon AM, McLean CA, McDonald PB and Kelly JW: Prognosis associated with cutaneous melanoma metastases. Australas J Dermatol. 56:25–28. 2015. View Article : Google Scholar : PubMed/NCBI
10	Lin X, Khalid S, Qureshi MZ, Attar R, Yaylim I, Ucak I, Yaqub A, Fayyaz S, Farooqi AA and Ismail M: VEGF mediated signaling in oral cancer. Cell Mol Biol (Noisy-le-grand). 62:64–68. 2016. View Article : Google Scholar : PubMed/NCBI
11	Oliveto S, Mancino M, Manfrini N and Biffo S: Role of microRNAs in translation regulation and cancer. World J Biol Chem. 8:45–56. 2017. View Article : Google Scholar : PubMed/NCBI
12	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
13	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
14	Stein M, Ruggiero P, Rappuoli R and Bagnoli F: Helicobacter pylori CagA: From pathogenic mechanisms to its use as an anti-cancer vaccine. Front Immunol. 4:3282013. View Article : Google Scholar : PubMed/NCBI
15	Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
16	Zhang R, Peng Y, Wang W and Su B: Rapid evolution of an X-linked microRNA cluster in primates. Genome Res. 17:612–617. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kunz M: MicroRNAs in melanoma biology. Adv Exp Med Biol. 774:103–120. 2013. View Article : Google Scholar : PubMed/NCBI
18	Shiiyama R, Fukushima S, Jinnin M, Yamashita J, Miyashita A, Nakahara S, Kogi A, Aoi J, Masuguchi S, Inoue Y and Ihn H: Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 23:366–372. 2013. View Article : Google Scholar : PubMed/NCBI
19	Tembe V, Schramm SJ, Stark MS, Patrick E, Jayaswal V, Tang YH, Barbour A, Hayward NK, Thompson JF, Scolyer RA, et al: MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. Pigment Cell Melanoma Res. 28:254–266. 2015. View Article : Google Scholar : PubMed/NCBI
20	Fleming NH, Zhong J, da Silva IP, de Miera Vega-Saenz E, Brady B, Han SW, Hanniford D, Wang J, Shapiro RL, Hernando E and Osman I: Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer. 121:51–59. 2015. View Article : Google Scholar : PubMed/NCBI
21	Thanarajasingam U, Sanz L, Diaz R, Qiao J, Sanchez-Perez L, Kottke T, Thompson J, Chester J and Vile RG: Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res. 67:300–308. 2007. View Article : Google Scholar : PubMed/NCBI
22	Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA and Mullins DW: CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. 64:7697–7701. 2004. View Article : Google Scholar : PubMed/NCBI
23	Latchana N, Ganju A, Howard JH and Carson WE III: MicroRNA dysregulation in melanoma. Surg Oncol. 25:184–189. 2016. View Article : Google Scholar : PubMed/NCBI
24	Li JZ, Gao W, Ho WK, Lei WB, Wei WI, Chan JY and Wong TS: The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: A meta-analysis. Chin J Cancer. 35:952016. View Article : Google Scholar : PubMed/NCBI
25	Mao XH, Chen M, Wang Y, Cui PG, Liu SB and Xu ZY: MicroRNA-21 regulates the ERK/NF-κB signaling pathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN. Mol Carcinog. 56:886–894. 2017. View Article : Google Scholar : PubMed/NCBI
26	Naves LB, Dhand C, Venugopal JR, Rajamani L, Ramakrishna S and Almeida L: Nanotechnology for the treatment of melanoma skin cancer. Prog Biomater. 6:13–26. 2017. View Article : Google Scholar : PubMed/NCBI
27	Mueller DW and Bosserhoff AK: Role of miRNAs in the progression of malignant melanoma. Br J Cancer. 101:551–556. 2009. View Article : Google Scholar : PubMed/NCBI
28	Zhang N, Wei X and Xu L: miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett. 587:2346–2351. 2013. View Article : Google Scholar : PubMed/NCBI
29	Tagawa H, Watanabe A and Sawada K: Abstract 146: The role of Mir-150 as a tumor suppressor in malignant lymphoma. Cancer Res. 71 8 Suppl:S1462011. View Article : Google Scholar
30	Li CH, Yu TB, Qiu HW, Zhao X, Zhou CL and Qi C: miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1. Oncol Lett. 13:2191–2197. 2017. View Article : Google Scholar : PubMed/NCBI
31	Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W and Qin H: miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 61:1447–1453. 2012. View Article : Google Scholar : PubMed/NCBI
32	Huang S, Chen Y, Wu W, Ouyang N, Chen J, Li H, Liu X, Su F, Lin L and Yao Y: miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One. 8:e807072013. View Article : Google Scholar : PubMed/NCBI
33	Friedman EB, Shang S, de Miera EV, Fog JU, Teilum MW, Ma MW, Berman RS, Shapiro RL, Pavlick AC, Hernando E, et al: Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med. 10:1552012. View Article : Google Scholar : PubMed/NCBI
34	Colburn NH, Yang HS and Jansen A: Pdcd4 targets eIF4A to inhibit translation, transcription, tumorigenesis and invasion. EJC Suppl. 4:232006. View Article : Google Scholar
35	Li JZ, Gao W, Lei WB, Zhao J, Chan JY, Wei WI, Ho WK and Wong TS: MicroRNA 744-3p promotes MMP-9-mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma. Oncotarget. 7:58218–58233. 2016. View Article : Google Scholar : PubMed/NCBI
36	Vikhreva PN and Korobko IV: Expression of Pdcd4 tumor suppressor in human melanoma cells. Anticancer Res. 34:2315–2318. 2014.PubMed/NCBI
37	Lei Y, Hu X, Li B, Peng M, Tong S, Zu X, Wang Z, Qi L and Chen M: miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro. Med Sci Monit. 20:1850–1857. 2014. View Article : Google Scholar : PubMed/NCBI